Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733276 | 0.92 | ALOX15 (0.50) | ALOX15ALOX12ESR1HSD17B3CES2 | |
| SCHEMBL28681881 | 0.77 | ABL1 (0.33) | — | |
| SCHEMBL14609269 | 0.72 | APP (0.43) | ALOX15HPGD | |
| SCHEMBL3438830 | 0.71 | ALOX15 (0.50) | ALOX15ALOX12ESR1HSD17B3CES2 | |
| SCHEMBL5380526 | 0.71 | — | — | |
| SCHEMBL5370217 | 0.71 | — | — | |
| SCHEMBL695248 | 0.70 | MAPT (0.53) | ALOX15HPGDCYP2C19DBH | |
| SCHEMBL4219698 | 0.70 | ALDH1A1 (0.50) | CYP2C9HPGD | |
| SCHEMBL694368 | 0.70 | CA3 (0.40) | ALOX15ESR1HPGDCASP1 | |
| SCHEMBL236958 | 0.70 | CYP2A6 (0.40) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053598-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2013-02-28 | — | — | US | disclosed |
| EP-2421822-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | Zylum Beteiligungsgesellschaft mbH & Co. Patente II KG (DE) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122105-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243768-A1 | Phenolic diazonium salt, method for its production and its application | Zylum Beteiligungsgesellschaft mbH & Co. Patente II KG (DE) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053598-A1 | METHOD FOR PRODUCING A CROSS-COUPLING PRODUCT OF A BENZENOID DIAZONIUM SALT | CBR3, CBR1, NOX3 | ALOX15 3884/4885ALOX12 3220/4885ESR1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.